December 1, 2020, Vol 324, No. 21, Pages 2131-2222
The Challenges Ahead With Monoclonal AntibodiesFrom Authorization to Access
Robert H. Goldstein, MD, PhD; Rochelle P. Walensky, MD, MPH
free access has active quiz
JAMA. 2020;324(21):2151-2152. doi:10.1001/jama.2020.21872
This Viewpoint discusses questions about clinical indication, supply, distribution, and cost and coverage that will need to be resolved if monoclonal antibodies are be granted Emergency Use Authorization or licensure and become available as treatment for COVID-19.